Skip to main content

AQUIPTA (Allergan Australia Pty Ltd)

Product name
AQUIPTA
Date registered
Evaluation commenced
Decision date
Approval time
211 (255 working days)
Active ingredients
atogepant
Registration type
NCE/NBE
Indication

AQUIPTA is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month

Help us improve the Therapeutic Goods Administration site